low molecular weight heparin & ischaemic stroke
Last reviewed 01/2018
There is mixed trial evidence concerning the use of low molecular weight heparin (LMWH) in patients with acute ischaemic stroke.
Some trials suggest a reduction in mortality/dependency at six months in those treated with LMWH.
However recent evidence suggests that LMWH has no significant benefit over aspirin for acute ischaemic stroke in patients with atrial fibrillation.